Product Details
| Product Name:
Terameprocol |
CAS No.:
24150-24-1 |
| Purity:
99.38% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Terameprocol |
| Description | Terameprocol (EM-1421) is a synthetic tetra-methylated derivative of nordihydroguaiaretic acid (NDGA) and transcriptional inhibitor with potential antiviral, antiangiogenic, and antineoplastic activities. Terameprocol showed the strongest anti-HIV activity. |
| In vitro | In Vero cells, Terameprocol inhibited Sp1 transcription factor binding at the HIV long terminal repeat promoter and at the α-ICP4 promoter with IC50 values of 11 and 43.5 μM, respectively. The IC50 of Terameprocol varied between 11.7 and 4 μM in 10 passages of HSV-1 and 4 passages of HSV-2 [2]. Terameprocol inhibited Sp1-dependent Cdc2 gene expression. In M4N-treated transformed C3 cells, Terameprocol induced growth arrest and apoptosis by suppressing Sp1-dependent Cdc2 and survivin gene expression giving rise to its antitumorigenic activity [3]. Terameprocol treatment suppressed expression of the Sp1-dependent survivin gene. In transiently and stably survivin-transfected C3 cells, Terameprocol reduced caspase-3 activation by 50% and 75%, respectively [3]. Terameprocol inhibited the growth of a number of tumor cell lines by inducing apoptosis in a non-schedule-dependent manner [4]. Terameprocol inhibited the synthesis of DNA by melanoma cells and causes cell cycle arrest in G0/G1 and G2/M phases of the cell cycle [4]. |
| In vivo | Terameprocol effectively inhibited the growth of human tumors in nude mice [5]. Terameprocol inhibited the growth of both murine and human melanomas and human colon cancer without apparent hepatic or renal toxicity [4]. In nude (nu/nu) mice bearing xenografts of human tumor types (Hep 3B, LNCaP, HT-29, MCF7, and K-562), treatment with Terameprocol (i.v. or i.p.) down-regulated Cdc2 and survivin genes expression [5]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 27.5 mg/ml (76.71 mM)
|
| Keywords | EM1421 | inhibit | LOX | Inhibitor | Lipoxygenase | EM 1421 | Terameprocol |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Inosine pranobex | Emtricitabine | Kaempferol | Dolutegravir intermediate-1 | Dextran sulfate sodium salt (MW 4500-5500) | Lamivudine | Chloroquine phosphate | Tenofovir Disoproxil Fumarate | Decanedioic acid | Tenofovir |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Viral Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Infection Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2251753-61-2
$545.00 / 1mg
-
CAS:3026677-37-9
$40.00 / 5mg
-
CAS:525-82-6
$42.00 / 500mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States